Skip to main content
Premium Trial:

Request an Annual Quote

DNAStar Names Inqaba Biotec as Distributor for Africa

NEW YORK – DNAStar has appointed Inqaba Biotechnical Industries as distributor of its DNA, RNA, and protein sequence analysis software in Africa.

DNAStar, based in Madison, Wisconsin, offers the Lasergene software suite, which provides molecular biologists, geneticists, and structural biologists with capabilities such as Sanger and next-generation sequencing assembly and analysis, protein sequence and structure analysis, and protein structure prediction.

Inqaba, a South African genomics company established in 2002, provides a wide array of products and services to the life sciences market in sub-Saharan Africa.

Inqaba has "a long history of successfully meeting the needs of molecular biologists in Africa, including meeting their software needs," Tom Schwei, vice president and general manager of DNAStar, said in a statement. "We have great confidence in Inqaba Biotec to support African customers with outstanding sales and customer service for our Lasergene software."

Financial terms were not disclosed.

In August, DNAStar said it had appointed Ships Bioscience as a nonexclusive but sole distributor of its products in Japan.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.